Innovative Platform Shennon Bio's proprietary single-cell profiling platform offers unprecedented throughput and accuracy in immune cell analysis, presenting opportunities to collaborate on advanced immunotherapy research and expand product integration into biotech pipelines.

Recent Funding Boost With a recent oversubscribed $13 million seed financing round led by notable investors like DCVC, Foundation Capital, and AV8, the company is poised for rapid growth and scaling of its platform, signaling potential for strategic partnerships and customer acquisition.

Market Focus Targeting applications in solid tumor and autoimmune disease therapies, Shennon Bio's technology aligns with growing market demands for more precise and effective immunotherapies, opening doors for medical device, biopharma, and research tool sales.

Funding and Revenue With current revenues between $1 million and $10 million and significant investor backing, there is an opportunity to offer complementary products, services, or consulting to accelerate their development and market entry.

Strategic Location Based in San Francisco near UCSF Mission Bay, Shennon Bio's proximity to leading research institutions makes it an ideal partner for collaborative projects, joint ventures, or technology licensing in cutting-edge immunotherapy research.